A00299 Summary:

BILL NOA00299
 
SAME ASNo Same As
 
SPONSORDinowitz
 
COSPNSR
 
MLTSPNSR
 
Amd SS3216, 3221 & 4303, Ins L
 
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Go to top    

A00299 Actions:

BILL NOA00299
 
01/07/2015referred to insurance
01/06/2016referred to insurance
Go to top

A00299 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)
 
BILL NUMBER: A299
 
SPONSOR: Dinowitz
  TITLE OF BILL: An act to amend the insurance law, in relation to reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs   PURPOSE OR GENERAL IDEA OF BILL: To authorize reimbursement for test- ing for Familial Dysautonomia, Canavan's disease and Tay-Sachs   SUMMARY OF PROVISIONS: Amends subsection (1) of Section 3216, subsection (1) of Section 3221 and Section 4303 of the Insurance Law, to authorize reimbursement for Familial Dysautonomia, Canavan's disease and Tay-Sachs testing. The bill also states that in order to maintain the confidentiality of persons tested, receipt of acknowledgment from the testing facility shall be deemed sufficient evidence of testing.   JUSTIFICATION: Familial Dysautonomia, Canavan's disease and Tay-Sachs are genetic diseases which cause degeneration of the nervous system, and result in death. No treatment is currently available for any of these diseases, however, an infant can only be afflicted with the disease if both the mother and father are carriers. There is currently a testing system in place which screens individuals before marriage to determine if they are carriers. This legislation would insure that individuals are able to receive reimbursement for medical screening for these diseases through their insurance carrier.   PRIOR LEGISLATIVE HISTORY: 2013-14- A.4372-A - Referred to Insurance/S.209-A - Referred to Insurance 2011-12- A.264 - Referred to Insurance/S.2880 -Referred to Insurance 2009-10- A.1134- Referred to Insurance 2007-08- A4447- Referred to Insurance 2005-06- A2424-A, Referred to Insurance 2003-04- A9263, Referred to Insurance   FISCAL IMPLICATIONS: None.   EFFECTIVE DATE: Immediately.
Go to top

A00299 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                           299
 
                               2015-2016 Regular Sessions
 
                   IN ASSEMBLY
 
                                       (Prefiled)
 
                                     January 7, 2015
                                       ___________
 
        Introduced by M. of A. DINOWITZ -- read once and referred to the Commit-
          tee on Insurance
 
        AN  ACT  to  amend  the  insurance law, in relation to reimbursement for
          testing for familial dysautonomia, Canavan's disease and Tay-Sachs
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  Subsection  (i)  of  section 3216 of the insurance law is
     2  amended by adding a new paragraph 32 to read as follows:
     3    (32) (A) Every policy which provides coverage for  hospital,  surgical
     4  or  medical  care  or  provides  reimbursement  for  laboratory tests or
     5  reimbursement for diagnostic X-ray services shall provide  coverage  for
     6  testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
     7    (B)  Such coverage shall be included at the inception of all new poli-
     8  cies and, with respect to all other policies, at any anniversary date of
     9  the policy subject to evidence of insurability.
    10    (C) For purposes of this paragraph, in order to maintain the confiden-
    11  tiality of persons tested, receipt of an acknowledgment from the labora-
    12  tory performing the test for familial  dysautonomia,  Canavan's  disease
    13  and  Tay-Sachs shall be deemed sufficient evidence of the performance of
    14  such testing.
    15    (D) Such coverage may be subject to annual  deductibles  and  co-insu-
    16  rance  as  may  be  deemed  appropriate by the superintendent and as are
    17  consistent with those established for  other  benefits  within  a  given
    18  policy.
    19    § 2. Subsection (l) of section 3221 of the insurance law is amended by
    20  adding a new paragraph 19 to read as follows:
    21    (19) (A) A group policy which provides coverage for hospital, surgical
    22  or  medical  care  or  provides  reimbursement  for  laboratory tests or
    23  reimbursement for diagnostic X-ray services shall provide  coverage  for
    24  testing for familial dysautonomia, Canavan's disease and Tay-Sachs.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD01076-01-5

        A. 299                              2
 
     1    (B)  Such coverage shall be included at the inception of all new poli-
     2  cies and, with respect to all other policies, at any anniversary date of
     3  the policy subject to evidence of insurability.
     4    (C) For purposes of this paragraph, in order to maintain the confiden-
     5  tiality of persons tested, receipt of an acknowledgment from the labora-
     6  tory  performing  the  test for familial dysautonomia, Canavan's disease
     7  and Tay-Sachs shall be deemed sufficient evidence of the performance  of
     8  such testing.
     9    (D)  Such  coverage  may be subject to annual deductibles and co-insu-
    10  rance as may be deemed appropriate by  the  superintendent  and  as  are
    11  consistent  with  those  established  for  other benefits within a given
    12  policy.
    13    § 3. Section 4303 of the insurance law is  amended  by  adding  a  new
    14  subsection (oo) to read as follows:
    15    (oo)  (1)  A medical expense indemnity corporation, a hospital service
    16  corporation or a health service corporation which provides coverage  for
    17  hospital, surgical or medical care or provides reimbursement for labora-
    18  tory  tests or reimbursement for diagnostic X-ray services shall provide
    19  coverage for testing for familial dysautonomia,  Canavan's  disease  and
    20  Tay-Sachs.
    21    (2)  Such coverage shall be included at the inception of all new poli-
    22  cies and, with respect to all other policies, at any anniversary date of
    23  the policy subject to evidence of insurability.
    24    (3) For purposes of this subsection, in order to maintain  the  confi-
    25  dentiality  of  persons  tested,  receipt  of an acknowledgment from the
    26  laboratory performing the  test  for  familial  dysautonomia,  Canavan's
    27  disease  and  Tay-Sachs  shall  be  deemed  sufficient  evidence  of the
    28  performance of such testing.
    29    (4) Such coverage may be subject to annual  deductibles  and  co-insu-
    30  rance  as  may  be  deemed  appropriate by the superintendent and as are
    31  consistent with those established for  other  benefits  within  a  given
    32  policy.
    33    § 4. This act shall take effect immediately.
Go to top